GlassScriptPhysician profile
John Y Karl
NPI 1831196773
$11,893.21
in general payments reported to CMS, 2019-2025
61 companies · $1,502 in 2025
The $1,502 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,790 · 2020: $1,052 · 2021: $2,102 · 2022: $1,788 · 2023: $1,783 · 2024: $1,877 · 2025: $1,502.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,969 · Education: $192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,969.47 |
| Education | $192.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,688.85 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $1,166.69 | 2019-2025 | Repatha, Otezla, Evenity |
| Abbvie INC. | $1,026.37 | 2019-2025 | |
| Pfizer INC. | $912.96 | 2019-2025 | |
| Astellas Pharma US INC | $911.78 | 2019-2025 | Veozah |
| Glaxosmithkline, LLC. | $689.90 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $624.98 | 2019-2025 | Farxiga, Airsupra |
| Amarin Pharma, INC. | $451.79 | 2019-2022 | |
| Lilly USA, LLC | $331.04 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Janssen Pharmaceuticals, INC | $260.66 | 2019-2023 | Xarelto |
| Xeris Pharmaceuticals, INC. | $258.04 | 2020-2025 | Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $207.81 | 2020-2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $203.68 | 2024-2025 | Voquezna |
| Sumitomo Pharma America, INC. | $202.15 | 2023-2024 | Gemtesa |
| Sanofi-Aventis U.S. LLC | $193.62 | 2019-2023 |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Karl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.